Literature DB >> 9107242

Wasting as independent risk factor for mortality in chronic heart failure.

S D Anker1, P Ponikowski, S Varney, T P Chua, A L Clark, K M Webb-Peploe, D Harrington, W J Kox, P A Poole-Wilson, A J Coats.   

Abstract

BACKGROUND: Wasting in chronic heart failure (CHF) has long been known but is little investigated. We sought to find out whether the cachectic state in CHF provides additional prognostic information about all-cause mortality.
METHODS: Between June, 1993, and May, 1995, we studied 171 consecutive patients with CHF (mean age 60 years [SD 11; range 27-86]; 17 female). We assessed exercise capacity (peak oxygen consumption; mean 17.5 mL kg-1 min-1 [6.7]), functional status (New York Heart Association [NYHA] class: 21 class I, 63 class II, 68 class III, 19 class IV), and left-ventricular ejection fraction (mean 30% [SD 15]; n = 115). The cachectic status was defined prospectively as a non-intentional documented weight loss of at least 7.5% of previous normal weight (28 patients; range 9-36% or 6-30 kg) during at least 6 months. The Cox proportional-hazards model was used to assess the association of variables with survival, and Kaplan-Meier cumulative survival plots were constructed to estimate the influence of risk factors.
FINDINGS: At the end of follow-up in November, 1996, 49 patients had died (after a mean 324 days [SD 283]). The mean follow-up of the survivors was 834 days (SD 186; range 549-1269). The cachectic state was predictive of 18-month mortality independent of age, NYHA class, left-ventricular ejection fraction, and peak oxygen consumption. Mortality in the cachectic patients (n = 28) was 18% at 3 months, 29% at 6 months, 39% at 12 months, and 50% at 18 months. Patients who had a peak oxygen consumption below 14 mL kg-1 min-1 (n = 53) had mortality at 3, 6, 12, and 18 months of 19%, 30%, 40%, and 51%. 18-month survival was 23% (95% CI 0-46) for the 13 patients with both of these risk factors (cachexia and low peak oxygen consumption) compared with 93% (88-98) in those (n = 103) with neither risk factor (p < 0.0001).
INTERPRETATION: The cachectic state is a strong independent risk factor for mortality in patients with CHF. Combined with a low peak oxygen consumption, it identifies a subset of patients at extremely high risk of death. Assessment of cachexia should be included in transplant programmes and studies that investigate the effect of interventions by survival analyses.

Entities:  

Mesh:

Year:  1997        PMID: 9107242     DOI: 10.1016/S0140-6736(96)07015-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  289 in total

1.  Insulin-like growth factor-I can be helpful towards end of life.

Authors:  A Bolger; W Doehner; S D Anker
Journal:  BMJ       Date:  2001-03-17

Review 2.  Statins and the role of nitric oxide in chronic heart failure.

Authors:  Stephan von Haehling; Stefan D Anker; Eberhard Bassenge
Journal:  Heart Fail Rev       Date:  2003-01       Impact factor: 4.214

3.  Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients.

Authors:  Mohammad Keilani; Christoph Krall; Christine Marosi; Birgit Flechl; Karin Dieckmann; Georg Widhalm; Maximilian Marhold; Richard Crevenna
Journal:  Wien Klin Wochenschr       Date:  2012-06-12       Impact factor: 1.704

4.  Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes.

Authors:  Marica Bordicchia; Dianxin Liu; Ez-Zoubir Amri; Gerard Ailhaud; Paolo Dessì-Fulgheri; Chaoying Zhang; Nobuyuki Takahashi; Riccardo Sarzani; Sheila Collins
Journal:  J Clin Invest       Date:  2012-02-06       Impact factor: 14.808

Review 5.  Testosterone and heart failure.

Authors:  Maurizio Volterrani; Giuseppe Rosano; Ferdinando Iellamo
Journal:  Endocrine       Date:  2012-06-24       Impact factor: 3.633

Review 6.  Impaired regeneration: A role for the muscle microenvironment in cancer cachexia.

Authors:  Erin E Talbert; Denis C Guttridge
Journal:  Semin Cell Dev Biol       Date:  2015-09-16       Impact factor: 7.727

7.  Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation.

Authors:  A Heidland; K Sebeková; A Frangiosa; L S De Santo; M Cirillo; F Rossi; M Cotrufo; A Perna; A Klassen; R Schinzel; N G De Santo
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

Review 8.  Thiamin deficiency and heart failure: the current knowledge and gaps in literature.

Authors:  Mavra Ahmed; Parastoo Azizi-Namini; Andrew T Yan; Mary Keith
Journal:  Heart Fail Rev       Date:  2015-01       Impact factor: 4.214

Review 9.  Muscle wasting and cachexia in heart failure: mechanisms and therapies.

Authors:  Stephan von Haehling; Nicole Ebner; Marcelo R Dos Santos; Jochen Springer; Stefan D Anker
Journal:  Nat Rev Cardiol       Date:  2017-04-24       Impact factor: 32.419

Review 10.  Heart failure: What causes the symptoms of heart failure?

Authors:  A J Coats
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.